Parkinson’s disease mutant Miro1 causes mitochondrial dysfunction and dopaminergic neuron loss

The complex and heterogeneous nature of Parkinson's disease (PD) is still not fully understood. However, increasing evidence supports mitochondrial impairment as a major driver of neurodegeneration. Miro1, a mitochondrial GTPase encoded by the RHOT1 gene, is involved in mitochondrial transport, mitophagy and mitochondrial calcium buffering, and is therefore essential for maintaining mitochondrial homeostasis. Recently, Miro1 has been linked genetically and pathophysiologically to PD, further supported by the identification of heterozygous variants of Miro1 in patients. Herein, we used patient-derived cellular models alongside knock-in mice to investigate Miro1-dependent pathophysiological processes and molecular mechanisms underlying neurodegeneration in PD. Experimental work performed in induced pluripotent stem cell (iPSC)-derived models, including midbrain organoids and dopaminergic neuronal cell cultures from a PD patient carrying the p.R272Q Miro1 mutation as well as healthy and isogenic controls, indicated that the p.R272Q Miro1 mutation leads to increased oxidative stress, disrupted mitochondrial bioenergetics and altered cellular metabolism. These changes were accompanied by increased α-synuclein levels and a significant reduction of dopaminergic neurons. Moreover, the p.R272Q Miro1 mutation-located in the calcium-binding domain of the GTPase-disrupted calcium homeostasis, resulting in calcium-dependent activation of calpain proteases and the subsequent cleavage of α-synuclein. Knock-in mice expressing p.R285Q Miro1 (the murine orthologue of the human p.R272Q mutation) displayed accumulation of phosphorylated α-synuclein in the striatum and a significant loss of dopaminergic neurons in the substantia nigra pars compacta, accompanied by behavioural alterations. These findings demonstrate that mutant Miro1 is sufficient to comprehensively model PD-relevant phenotypes in vitro and in vivo, reinforcing its pivotal role in PD pathogenesis.

Authors

Institutions

Publication Details

Journal
Brain
Published
2025-02-05
DOI
https://doi.org/10.1093/brain/awaf051
Citations
13
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
18.06

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Parkinson’s disease mutant Miro1 causes mitochondrial dysfunction and dopaminergic neuron loss

Manuel Buttini, Cláudia Saraiva, Thorsten Schmidt, Alise Žagare et al.
13 citations
Brain
Parkinson's Disease Mechanisms and Treatments
18.06
article

Parkinson’s disease mutant Miro1 causes mitochondrial dysfunction and dopaminergic neuron loss

Manuel Buttini, Cláudia Saraiva, Thorsten Schmidt, Alise Žagare, Frida Lind‐Holm Mogensen, Anne‐Marie Marzesco, Kyriaki Barmpa, Alessandro Michelucci, Pierre Garcia, Ginevra Sacripanti, Jochen Ohnmacht, Jaqueline Jung, Jens C. Schwamborn, Axel Chemla, Vyron Gorgogietas, Alexandre Baron, Rejko Krueger, Anne Grünewald, Paul Antony
article en
13 citations

Abstract

The complex and heterogeneous nature of Parkinson's disease (PD) is still not fully understood. However, increasing evidence supports mitochondrial impairment as a major driver of neurodegeneration. Miro1, a mitochondrial GTPase encoded by the RHOT1 gene, is involved in mitochondrial transport, mitophagy and mitochondrial calcium buffering, and is therefore essential for maintaining mitochondrial homeostasis. Recently, Miro1 has been linked genetically and pathophysiologically to PD, further supported by the identification of heterozygous variants of Miro1 in patients. Herein, we used patient-derived cellular models alongside knock-in mice to investigate Miro1-dependent pathophysiological processes and molecular mechanisms underlying neurodegeneration in PD. Experimental work performed in induced pluripotent stem cell (iPSC)-derived models, including midbrain organoids and dopaminergic neuronal cell cultures from a PD patient carrying the p.R272Q Miro1 mutation as well as healthy and isogenic controls, indicated that the p.R272Q Miro1 mutation leads to increased oxidative stress, disrupted mitochondrial bioenergetics and altered cellular metabolism. These changes were accompanied by increased α-synuclein levels and a significant reduction of dopaminergic neurons. Moreover, the p.R272Q Miro1 mutation-located in the calcium-binding domain of the GTPase-disrupted calcium homeostasis, resulting in calcium-dependent activation of calpain proteases and the subsequent cleavage of α-synuclein. Knock-in mice expressing p.R285Q Miro1 (the murine orthologue of the human p.R272Q mutation) displayed accumulation of phosphorylated α-synuclein in the striatum and a significant loss of dopaminergic neurons in the substantia nigra pars compacta, accompanied by behavioural alterations. These findings demonstrate that mutant Miro1 is sufficient to comprehensively model PD-relevant phenotypes in vitro and in vivo, reinforcing its pivotal role in PD pathogenesis.

BrainVol. 148(10)
Centre Hospitalier de Luxembourg (LU), University of Luxembourg (LU), Luxembourg Institute of Health (LU), Laboratoire National de Santé (LU), University of Tübingen (DE), University of Lübeck (DE)
Prothena, Fonds National de la Recherche Luxembourg, Helmholtz Zentrum München
Good health and well-being
Openalex Percentile: Top 1%
Parkinson's Disease Mechanisms and Treatments
18.06
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.